Get the Stockscreener App
0.2536
1.85%
0.0046
Bioaffinity Technologies Inc stock is traded at $0.2536, with a volume of 224.59K.
It is up +1.85% in the last 24 hours and down -26.06% over the past month.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
See More
Previous Close:
$0.249
Open:
$0.242
24h Volume:
224.59K
Relative Volume:
0.03
Market Cap:
$7.22M
Revenue:
$9.37M
Net Income/Loss:
$-8.45M
P/E Ratio:
-0.3131
EPS:
-0.81
Net Cash Flow:
$-7.27M
1W Performance:
+8.79%
1M Performance:
-26.06%
6M Performance:
-69.45%
1Y Performance:
-85.43%
1-Day Range:
$0.242
$0.267
1-Week Range:
$0.2321
$0.2781
52-Week Range:
$0.1639
$2.2592
Bioaffinity Technologies Inc Stock (BIAF) Company Profile
Name
Bioaffinity Technologies Inc
Sector
Industry
Phone
210-698-5334
Address
3300 NACOGDOCHES ROAD, SAN ANTONIO
Compare BIAF with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIAF
Bioaffinity Technologies Inc
|
0.2536 | 6.97M | 9.37M | -8.45M | -7.27M | -0.81 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Bioaffinity Technologies Inc Stock (BIAF) Latest News
Heatmap Data Shows High Activity in bioAffinity Technologies Inc. Equity Warrant SectorJuly 2025 Catalysts & Technical Pattern Alert System - thegnnews.com
bioAffinity Technologies Appoints New Members to Board of Directors - BioSpace
bioAffinity Technologies Appoints New Board Members - TipRanks
bioAffinity Technologies Appoints Roberto Rios, CPA, and John J. Oppenheimer, M.D., To Board - citybiz
Board Strengthening and Strategic Growth in Bioaffinity Technologies - AInvest
Bioaffinity Technologies appoints new members to board of directors - MarketScreener
Bioaffinity Technologies Appoints New Members To Board Of Directors - TradingView
bioAffinity Technologies appoints two new directors to board By Investing.com - Investing.com South Africa
bioAffinity Technologies appoints two new directors to board - Investing.com India
Can bioAffinity Technologies Inc. be recession proof2025 Dividend Review & Entry Point Strategy Guides - newsimpact.co.kr
What makes bioAffinity Technologies Inc. Equity Warrant stock price move sharply2025 Price Action Summary & Weekly Breakout Stock Alerts - classian.co.kr
bioAffinity Technologies Inc. Equity Warrant Breaks Losing Streak — Is the Trend ReversingMarket Volume Summary & High Accuracy Trade Signal Alerts - beatles.ru
Chart Analysts Warn of Resistance Near bioAffinity Technologies Inc. Price2025 Earnings Surprises & Precise Trade Entry Recommendations - kangso.co.kr
bioAffinity Technologies Secures $1.2M Through Private Placement - The Globe and Mail
bioAffinity 2025 Q2 Earnings Continued Losses Despite Operational Optimism - AInvest
bioAffinity Technologies Sees Surge in CyPath® Lung Test Sales - MSN
bioAffinity Technologies Raises $1.2 Million through Private Placement and Warrant Inducement Transactions - AInvest
bioAffinity Technologies Inc. Equity Warrant Shows Early Signs of Technical StrengthWeekly Stock Analysis & Consistent Profit Focused Trading Strategies - sundaytimes.kr
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - BioSpace
bioAffinity Technologies Reports Strong Growth in Lung Test Sales - TipRanks
bioAffinity Misses Q2 Revenue Target - AOL.com
BioAffinity Technologies raises $1.2mln in private placement, warrant inducement transaction. - AInvest
bioAffinity Technologies Reports Q2 Revenue Miss, EPS Wider Than Expected - AInvest
bioAffinity Technologies, Inc. SEC 10-Q Report - TradingView
BioAffinity Technologies, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
WallachBeth Capital Announces Closing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Yahoo Finance
BioAffinity Technologies Completes Private Placement and Warrant Inducement for $1.2 Million in Gross Proceeds. - AInvest
BioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - MarketScreener
bioAffinity Technologies Announces Closing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds | FinancialContent - FinancialContent
bioAffinity Technologies earnings missed by $0.07, revenue topped estimates - Investing.com Canada
bioAffinity Technologies Reports Second Quarter 2025 Results - Bluefield Daily Telegraph
Published on: 2025-08-14 05:42:08 - Newser
What recovery options are there for bioAffinity Technologies Inc. Equity WarrantTake Profit & Risk Controlled Daily Trade Plans - Newser
bioAffinity Technologies Sees Surge in CyPath Lung Test Sales Amid Nasdaq Compliance Concerns - AInvest
bioAffinity Technologies Announces Pricing of Private Placement and Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - BioSpace
bioAffinity Technologies announces pricing of private placement - MSN
Custom watchlist performance reports with bioAffinity Technologies Inc. Equity WarrantMarket Sentiment Report & Consistent Income Trade Recommendations - Newser
Combining machine learning predictions for bioAffinity Technologies Inc.Quarterly Performance Summary & Risk Managed Trade Strategies - Newser
BioAffinity Technologies announces surge in CyPath Lung sales - TipRanks
BioAffinity Technologies Raises $1.2 Million in Private Placement - MarketScreener
WallachBeth Capital Announces Pricing of bioAffinity Technologies Private Placement and Concurrent Warrant Inducement Transaction for Approximately $1.2 Million in Gross Proceeds - Finansavisen
BioAffinity Technologies raises $990 mln through preferred stock and warrant sale. - AInvest
bioAffinity Technologies raises $1.2 million in private placement By Investing.com - Investing.com Australia
bioAffinity Technologies raises $1.2 million in private placement - Investing.com
bioAffinity Secures Fresh Capital as Investors Back Early-Stage Cancer Detection Technology - Stock Titan
RBC Global Asset Management Inc. announces final details on maturity of RBC Target 2025 Canadian Government Bond ETF, RBC Target 2025 Canadian Corporate Bond Index ETF and RBC Target 2025 U.S. Corporate Bond ETF - The Globe and Mail
Navigating Dilution and Growth: bioAffinity Technologies' Warrant Strategy in the Biotech Landscape - AInvest
Early Cancer Detection Biotech Secures $1.2M Funding to Advance Noninvasive Testing Technology - Stock Titan
BioAffinity Technologies Announces $1.2M Capital Raise Through Private Placement Of 990 Series B Preferred Shares Convertible Into 4.3M Common Shares At $0.23/Share And 6.7M Warrants At $0.352/Share, Plus $253K Warrant Inducement For Immediat - 富途牛牛
BioAffinity Technologies Raises $1.2 Million in Private Placement and Warrant Inducement Transaction. - AInvest
D-Wave Quantum vs. IonQ: Which is the Better Quantum Computing Stock? - The Globe and Mail
Bioaffinity Technologies Inc Stock (BIAF) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):